Prima BioMed (NASDAQ:IMMP) and BioCardia (NASDAQ:BCDA) Financial Contrast

Prima BioMed (NASDAQ:IMMP) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.

Profitability

This table compares Prima BioMed and BioCardia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
BioCardia	N/A	-5,456.14%	-232.75%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Prima BioMed and BioCardia, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1	3	0	0	1.75
BioCardia	1	1	1	0	2.00

Prima BioMed presently has a consensus price target of $5.50, suggesting a potential upside of 1,385.28%. BioCardia has a consensus price target of $25.00, suggesting a potential upside of 2,900.84%. Given BioCardia’s stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Prima BioMed.

Volatility and Risk

Prima BioMed has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Institutional & Insider Ownership

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 17.4% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Prima BioMed and BioCardia”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69 million	8.16	-$39.78 million	N/A	N/A
BioCardia	$60,000.00	158.01	-$8.23 million	($0.91)	-0.92

BioCardia has lower revenue, but higher earnings than Prima BioMed.

Summary

BioCardia beats Prima BioMed on 7 of the 11 factors compared between the two stocks.

About Prima BioMed

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.